About: Hepatitis Associated Aplastic Anemia: A review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hepatitis Associated Aplastic Anemia: A review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hepatitis Associated Aplastic Anemia: A review
Creator	Ali, Muhammad Idrees, Muhammad Butt, Azeem Amjad, Shahida Hussain, Abrar Shah, Riaz Ali, Liaqat Butt, Sadia Rauff, Bisma
Source	PMC
abstract	Hepatitis-associated aplastic anemia (HAAA) is an uncommon but distinct variant of aplastic anemia in which pancytopenia appears two to three months after an acute attack of hepatitis. HAAA occurs most frequently in young male children and is lethal if leave untreated. The etiology of this syndrome is proposed to be attributed to various hepatitis and non hepatitis viruses. Several hepatitis viruses such as HAV, HBV, HCV, HDV, HEV and HGV have been associated with this set of symptoms. Viruses other than the hepatitis viruses such as parvovirus B19, Cytomegalovirus, Epstein bar virus, Transfusion Transmitted virus (TTV) and non-A-E hepatitis virus (unknown viruses) has also been documented to develop the syndrome. Considerable evidences including the clinical features, severe imbalance of the T cell immune system and effective response to immunosuppressive therapy strongly present HAAA as an immune mediated mechanism. However, no association of HAAA has been found with blood transfusions, drugs and toxins. Besides hepatitis and non hepatitis viruses and immunopathogenesis phenomenon as causative agents of the disorder, telomerase mutation, a genetic factor has also been predisposed for the development of aplastic anemia. Diagnosis includes clinical manifestations, blood profiling, viral serological markers testing, immune functioning and bone marrow hypocellularity examination. Patients presenting the features of HAAA have been mostly treated with bone marrow or hematopoietic cell transplantation from HLA matched donor, and if not available then by immunosuppressive therapy. New therapeutic approaches involve the administration of steroids especially the glucocorticoids to augment the immunosuppressive therapy response. Pancytopenia following an episode of acute hepatitis response better to hematopoietic cell transplantation than immunosuppressive therapy.
has issue date	2011-02-28(xsd:dateTime)
bibo:doi	10.1186/1743-422x-8-87
bibo:pmid	21352606
has license	cc-by
sha1sum (hex)	6e82d495f9c8238f815a1586adbad8380d9ec38c
schema:url	https://doi.org/10.1186/1743-422x-8-87
resource representing a document's title	Hepatitis Associated Aplastic Anemia: A review
has PubMed Central identifier	PMC3052191
has PubMed identifier	21352606
schema:publication	Virol J
resource representing a document's body	covid:6e82d495f9c8238f815a1586adbad8380d9ec38c#body_text
is schema:about of	named entity 'mediated' named entity 'aplastic anemia' named entity 'set' named entity 'effective' named entity 'immunosuppressive therapy' named entity 'immune system' named entity 'hepatitis viruses' named entity 'HLA' named entity 'BLOOD TRANSFUSIONS' named entity 'VARIANT' covid:arg/6e82d495f9c8238f815a1586adbad8380d9ec38c named entity 'HCV' named entity 'factor' named entity 'disorder' named entity 'TTV' named entity 'bone marrow' named entity 'aplastic anemia' named entity 'bar' named entity 'agents' named entity 'immunosuppressive therapy' named entity 'viruses' named entity 'However' named entity 'therapeutic' named entity 'manifestations' named entity 'T cell' named entity 'bone marrow' named entity 'hepatitis' named entity 'HDV' named entity 'hepatitis viruses' named entity 'immunosuppressive therapy' named entity 'HCV' named entity 'therapeutic approaches' named entity 'hepatitis' named entity 'hepatitis viruses' named entity 'aplastic anemia' named entity 'hepatitis' named entity 'hematopoietic cell' named entity 'immunopathogenesis' named entity 'bone marrow' named entity 'telomerase' named entity 'hepatitis viruses' named entity 'Aplastic Anemia' named entity 'etiological agent' named entity 'telomerase reverse transcriptase' named entity 'Bone marrow transplantation' named entity 'set of symptoms' named entity 'serum' named entity 'HSCs' named entity 'congenital' named entity 'CD8' named entity 'interleukin-3' named entity 'liver' named entity 'acute hepatitis' named entity 'cytotoxic' named entity 'hepatitis' named entity 'causative agent' named entity 'self-limiting' named entity 'fatality rate' named entity 'HLA-DR' named entity 'bone marrow' named entity 'interleukin-1' named entity 'bone marrow' named entity 'seropositivity' named entity 'cytotoxic' named entity 'hepatitis' named entity 'HGV' named entity 'TTV' named entity 'hepatitis E virus' named entity 'Cyclosporine' named entity 'CD2' named entity 'CD8' named entity 'TNF-α' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software